Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

Rhea-AI Summary

Eledon Pharmaceuticals plans to release its financial results for the fourth quarter and full year ended December 31, 2022, on March 30, 2023, following the close of trading. A conference call and webcast will be hosted at 4:30 p.m. ET on the same day. Investors can join via toll-free and international numbers or access the webcast link provided in the announcement. Eledon, a clinical-stage biotechnology company headquartered in Irvine, California, focuses on developing treatments targeting the CD40 Ligand pathway, with its lead compound being tegoprubart, an anti-CD40L antibody.

Positive

• Eledon is advancing its lead compound, tegoprubart, targeting a well-validated biological pathway with broad therapeutic potential.
• The scheduled conference call suggests transparency and ongoing communication with investors.

Negative

• None.

Management to host conference call and webcast at 4:30 p.m. ET

IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 30, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast Details:

Thursday, March 30, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-300-8521
International: 412-317-6026
Conference ID: 10175955
Webcast: https://ir.eledon.com/events-and-presentations/events

After the live webcast, the event will be archived on Eledon’s website for one year.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

Source: Eledon Pharmaceuticals

FAQ

When will Eledon Pharmaceuticals release its financial results?

Eledon Pharmaceuticals will release its financial results on March 30, 2023.

What time is the Eledon Pharmaceuticals conference call?

The conference call will be held at 4:30 p.m. ET on March 30, 2023.

What is the lead compound of Eledon Pharmaceuticals?

Eledon's lead compound is tegoprubart, an anti-CD40L antibody.

How can I access the Eledon Pharmaceuticals conference call?

You can access the conference call via toll-free number 877-300-8521 or international number 412-317-6026, using Conference ID 10175955.

Where is Eledon Pharmaceuticals headquartered?

Eledon Pharmaceuticals is headquartered in Irvine, California.